Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enVVeno MedicalNVNOW 30 3-Year EBITDA Growth Rate is 23.00% as of Jun. 2026, which is 0% below its 10-year median of 23.10. GuruFocus rates NVNOW with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, enVVeno Medical ranks better than 69.48% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 26.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 20.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of enVVeno Medical was 50.60% per year. The lowest was -83.10% per year. And the median was 23.10% per year.
enVVeno Medical (NAS:NVNOW) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
enVVeno Medical 3-Year EBITDA Growth Rate Related Terms
NVNOW vs ICCM, TRIB, AIDX: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, enVVeno Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's 3-Year EBITDA Growth Rate falls into.
enVVeno Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.00% mean?
enVVeno Medical (NVNOW) has a 3-Year EBITDA Growth Rate of 23.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for enVVeno Medical and its competitors. This is near median its historical median of 23.10. According to the industry distribution chart, enVVeno Medical ranks #210 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is enVVeno Medical's 3-Year EBITDA Growth Rate too high?
enVVeno Medical's current 3-Year EBITDA Growth Rate of 23.00% is near median its 10-year median of 23.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. enVVeno Medical's value of 23.00% is 191.1% above this industry median. Based on the distribution chart, enVVeno Medical ranks #210 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, enVVeno Medical has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's 3-Year EBITDA Growth Rate compare to ICCM and TRIB?
According to the Medical Devices & Instruments industry distribution chart, enVVeno Medical ranks #210 out of 688 companies for 3-Year EBITDA Growth Rate. This puts enVVeno Medical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. enVVeno Medical's value of 23.00% is 191.1% above this benchmark. While the company's 10-year median is 23.10 vs. the industry median of 7.90, enVVeno Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enVVeno Medical's current 3-Year EBITDA Growth Rate of 23.00% is 191.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for enVVeno Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enVVeno Medical's current 3-Year EBITDA Growth Rate is 23.00%, which is near median its own 10-year median of 23.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNOW) has a current 3-Year EBITDA Growth Rate of 23.00%. The current 3-Year EBITDA Growth Rate is 23.00%, which is near median its 10-year median of 23.10 and 191.1% above the Medical Devices & Instruments industry median of 7.90. enVVeno Medical's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For enVVeno Medical (NVNOW), the current 3-Year EBITDA Growth Rate is 23.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
30GF Score
Get the complete analysis for NVNOW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNOW has been successfully added to your 
